Effects of Proton Pump Inhibitors on Adverse Gastrointestinal Events in Patients Receiving Clopidogrel

  title={Effects of Proton Pump Inhibitors on Adverse Gastrointestinal Events in Patients Receiving Clopidogrel},
  author={Chun Shing Kwok and Ramanpreet Singh Nijjar and Yoon Kong Loke},
  journal={Drug Safety},
AbstractBackground: There has been recent concern regarding a possible adverse interaction between clopidogrel and proton pump inhibitors (PPIs), coupled with uncertainty as to whether PPIs genuinely help in reducing gastrointestinal (GI) harm. Objective: To perform a meta-analysis of GI outcomes in patients taking clopidogrel, with and without concomitant PPI. Methods: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register from inception to March 2010, and checked conference… 

Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

Platelet function studies do not demonstrate a clear or consistent interaction between clopidogrel and PPIs, and these studies are difficult to interpret given the lack of information on drug exposure, variation in laboratory methodology and lack of genetic information.

Effects of Proton Pump Inhibitors in Patients Receiving Clopidogrel

Patients using the combination of clopidogrel and a PPI are at an increased (absolute) risk of cardiovascular and gastrointestinal adverse outcomes, and physicians should interpret the results of these meta-analyses with caution.

Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors

Higher quality data from randomised trials indicate that use of PPI therapy for up to 6 months is unlikely to cause any adverse interaction with clopidogrel, and there are gastrointestinal benefits with PPI use.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Because PPI induced risk reduction clearly overweighs the possible adverse cardiovascular risk in patients with high risk of gastrointestinal bleeding, combination of clopidogrel with the less CYP2C19 inhibiting pantoprazole should be recommended.

Recent safety concerns with proton pump inhibitors.

There have been recent concerns about the safety of proton pump inhibitors (PPIs). We focus here on 3 specific concerns-the possible interaction between PPIs and clopidogrel, the postulated link

Antiplatelet drug interactions with proton pump inhibitors

An overview of the currently approved antiplatelet agents and PPIs, including their metabolic pathways is provided, and the CYP450 isoenzyme at the center of the drug interaction, CYP2C19, is described in detail.

The interaction between proton pump inhibitors and clopidogrel and upper gastrointestinal bleeding.

Antiplatelet therapy and proton pump inhibition: cause for concern?

The drug–drug interaction between antiplatelet agents and PPIs at the enzymatic level does not seem to result in worse clinical outcomes, and clinicians should use PPIs in selected high-risk patients to prevent gastrointestinal bleeding.

Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.

Compared with PPI non-use, current continuous PPI use was not associated with a significant change in risk of non-fatal myocardial infarction/coronary death among current continuous users of clopidogrel monotherapy.



Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors

In patients with serious coronary heart disease treated with clopidogrel, concurrent PPI use was associated with reduced incidence of hospitalizations for gastroduodenal bleeding, and the corresponding point estimate for serious cardiovascular disease was not increased.

Upper Gastrointestinal Bleeding in Patients with Aspirin and Clopidogrel Co-Therapy

The occurrence of UGIB associated with A+C co-therapy for a median of 5.8 months was 4.0%.

Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.

Concomitant use of an anti-secretory agent was associated with a reduced risk of UGI bleeding and use of PPI may be associated with an attenuation of the effect of dual antiplatelet therapy.

Proton pump inhibitors and clopidogrel: putting the interaction in perspective.

It is concluded that although adding a PPI to clopidogrel therapy may increase the risk of adverse events, the incremental risk is probably not very large, and the authors conclude that this interpretation is a sensible one.

Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, the data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase.

PPI use in patients commenced on clopidogrel: a retrospective cross‐sectional evaluation

This study assessed how many patients in the Royal Darwin Hospital and the Royal Hobart Hospital prescribed clopidogrel and at risk of bleeding were co‐prescribed PPIs.

Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants

Antisecretory agent or nitrate treatment is associated with reduced UGIB RR in patients taking NSAID or aspirin, and protection was not apparent in patientsTaking anticoagulants.

Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use

Data published since 1997 suggest that mortality in patients suffering from an upper gastrointestinal bleed or perforation has fallen to 1 in 13 overall, but remains higher at about 1 in 5 in those exposed to NSAID or aspirin.

Meta‐analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

This poster presents a small number of animal studies that suggest an adverse interaction between proton pump inhibitors (PPI) and clopidogrel and suggest the need to investigate further the mechanism behind this interaction.